179 related articles for article (PubMed ID: 26017797)
1. Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil.
Novaes HM; Itria A; Silva GA; Sartori AM; Rama CH; Soárez PC
Clinics (Sao Paulo); 2015 Apr; 70(4):289-95. PubMed ID: 26017797
[TBL] [Abstract][Full Text] [Related]
2. Estimation of the Costs of Invasive Cervical Cancer Treatment in Brazil: A Micro-Costing Study.
Santos CL; Souza AI; Figueiroa JN; Vidal SA
Rev Bras Ginecol Obstet; 2019 Jun; 41(6):387-393. PubMed ID: 31247667
[TBL] [Abstract][Full Text] [Related]
3. The economic burden of cervical cancer in Eswatini: Societal perspective.
Ngcamphalala C; Östensson E; Ginindza TG
PLoS One; 2021; 16(4):e0250113. PubMed ID: 33857233
[TBL] [Abstract][Full Text] [Related]
4. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
5. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
Brown RE; Breugelmans JG; Theodoratou D; Bénard S
Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
7. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
8. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
9. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Watson M; Lowy DR; Markowitz LE
Vaccine; 2012 Sep; 30(42):6016-9. PubMed ID: 22867718
[TBL] [Abstract][Full Text] [Related]
10. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
12. [Annual cost of ischemic heart disease in Brazil. Public and private perspective].
Ribeiro RA; Mello RG; Melchior R; Dill JC; Hohmann CB; Lucchese AM; Stein R; Ribeiro JP; Polanczyk CA
Arq Bras Cardiol; 2005 Jul; 85(1):3-8. PubMed ID: 16041447
[TBL] [Abstract][Full Text] [Related]
13. The economic burden of cervical cancer from diagnosis to one year after final discharge in Henan Province, China: A retrospective case series study.
Wu Q; Jia M; Chen H; Zhang S; Liu Y; Prem K; Qian M; Yu H
PLoS One; 2020; 15(5):e0232129. PubMed ID: 32379783
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
Praditsitthikorn N; Teerawattananon Y; Tantivess S; Limwattananon S; Riewpaiboon A; Chichareon S; Ieumwananonthachai N; Tangcharoensathien V
Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
[TBL] [Abstract][Full Text] [Related]
15. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
[TBL] [Abstract][Full Text] [Related]
16. [Private health expenditures in Brazil].
Ocké-Reis CO
Cad Saude Publica; 2015 Jul; 31(7):1351-3. PubMed ID: 26248091
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
18. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada.
Righolt CH; Pabla G; Mahmud SM
Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769
[TBL] [Abstract][Full Text] [Related]
19. Cost of Treatment for Cervical Cancer in India.
Singh MP; Chauhan AS; Rai B; Ghoshal S; Prinja S
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2639-2646. PubMed ID: 32986363
[TBL] [Abstract][Full Text] [Related]
20. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
